Vanda Pharmaceuticals (VNDA) Tops Q4 EPS by 4c; Guides Lower
Tweet
Share
E-mail
Get Alerts VNDA Hot Sheet
Price: $5.33 -1.84%
Revenue Growth %: +24.1%
Financial Fact:
Product sales: 38.48M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +24.1%
Financial Fact:
Product sales: 38.48M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q4 EPS of $0.12, $0.04 better than the analyst estimate of $0.08. Revenue for the quarter came in at $68 million versus the consensus estimate of $70.04 million.
GUIDANCE:
Vanda Pharmaceuticals sees FY2022 revenue of $240-280 million, versus the consensus of $313.62 million.
For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Casey's General Stores (CASY) Tops Q1 EPS by 69c
- UBS upgrades Lockheed Martin to Buy, sees 26% upside on missile growth
- Braze, Inc. (BRZE) Tops Q2 EPS by 4c; offers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
